Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA to prioritize review of Novartis STAMP inhibitor asciminib for chronic myeloid leukemia

The drug had previously won two breakthrough therapy designations.

By Brian Buntz | August 25, 2021

NovartisNovartis (NYSE:NVS) has announced that the FDA has granted priority review for its application for allosteric inhibitor asciminib (ABL001) in chronic myeloid leukemia (CML).

The drug targets the ABL myristoyl pocket (STAMP).

The priority review status could trim four months off the review time, dropping the review period to eight months from 12 months under a standard review.

Novartis won the status after sharing positive data from its Phase 3 ASCEMBL trial, which pitted asciminib against Pfizer’s Bosulif (bosutinib) in participants with Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP). Patients in the trial had received prior treatment with two or more tyrosine-kinase inhibitors (TKIs).

The prognosis for chronic myeloid leukemia has improved considerably since 2001, when promising treatments for the blood cancer began to emerge. Nevertheless, many people with CML face a risk of disease progression.

Sequential therapy with tyrosine-kinase inhibitors could lead to increased resistance or significant side effects, as a 2019 NEJM article explains.

FDA has granted two breakthrough therapy designations to asciminib and has also granted it orphan drug status.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: ABL001, ASCEMBL, Asciminib, chronic myeloid leukemia, FDA, Novartis
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50